Patients who are 18 years or older with persistent chronic lymphocytic leukemia or small lymphocytic lymphoma are currently being recruited for a Phase II study of Aezea® (EL625) in partnership with Duke University.

Additional Information: clinicaltrials.gov

Eleos has completed accrual for its Phase II clinical trials for patients with acute myelogenous leukemia (AML) in California, Florida, Missouri, New York and Texas.

For information about upcoming trials, please contact Eleos.